<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0"
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main" xml:id="_hpSxGMV">The three-year evolution of Germany&apos;s Digital Therapeutics reimbursement program and its path forward Check for updates</title>
				<funder>
					<orgName type="full">Projekt DEAL</orgName>
				</funder>
				<funder ref="#_tkFvHpx">
					<orgName type="full">Deutsche Forschungsgemeinschaft (DFG, German Research Foundation</orgName>
				</funder>
				<funder>
					<orgName type="full">HPI Research School on Data Science and Engineering</orgName>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Linea</forename><surname>Schmidt</surname></persName>
							<idno type="ORCID">0009-0006-3014-4058</idno>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Hasso Plattner Institute , Digital Engineering Faculty , University of Potsdam , Potsdam , Germany.</note>
								<orgName type="department">Digital Engineering Faculty</orgName>
								<orgName type="institution" key="instit1">Hasso Plattner Institute</orgName>
								<orgName type="institution" key="instit2">University of Potsdam</orgName>
								<address>
									<settlement>Potsdam</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>2</label> Hasso Plattner Institute for Digital Health at Mount Sinai , Icahn School of Medicine at Mount Sinai , New York , NY , USA.</note>
								<orgName type="department">Icahn School of Medicine</orgName>
								<orgName type="institution" key="instit1">Hasso Plattner Institute for Digital Health at Mount Sinai</orgName>
								<orgName type="institution" key="instit2">at Mount Sinai</orgName>
								<address>
									<settlement>New York</settlement>
									<region>NY</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<note type="raw_affiliation"><label>3</label> Windreich Dept. of Artificial Intelligence &amp; Human Health , Icahn School of Medicine at Mount Sinai , New York , NY , USA.</note>
								<orgName type="department">Windreich Dept. of Artificial Intelligence &amp; Human Health</orgName>
								<orgName type="institution">Icahn School of Medicine at Mount Sinai</orgName>
								<address>
									<settlement>New York</settlement>
									<region>NY</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Marc</forename><surname>Pawlitzki</surname></persName>
							<affiliation key="aff3">
								<note type="raw_affiliation"><label>4</label> Department of Neurology , Medical Faculty and University Hospital Düsseldorf , Heinrich Heine University Düsseldorf , Düsseldorf , Germany.</note>
								<orgName type="department" key="dep1">Department of Neurology</orgName>
								<orgName type="department" key="dep2">Medical Faculty</orgName>
								<orgName type="institution" key="instit1">University Hospital Düsseldorf</orgName>
								<orgName type="institution" key="instit2">Heinrich Heine University Düsseldorf</orgName>
								<address>
									<settlement>Düsseldorf</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Bernhard</forename><forename type="middle">Y</forename><surname>Renard</surname></persName>
							<idno type="ORCID">0000-0003-4589-9809</idno>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Hasso Plattner Institute , Digital Engineering Faculty , University of Potsdam , Potsdam , Germany.</note>
								<orgName type="department">Digital Engineering Faculty</orgName>
								<orgName type="institution" key="instit1">Hasso Plattner Institute</orgName>
								<orgName type="institution" key="instit2">University of Potsdam</orgName>
								<address>
									<settlement>Potsdam</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>2</label> Hasso Plattner Institute for Digital Health at Mount Sinai , Icahn School of Medicine at Mount Sinai , New York , NY , USA.</note>
								<orgName type="department">Icahn School of Medicine</orgName>
								<orgName type="institution" key="instit1">Hasso Plattner Institute for Digital Health at Mount Sinai</orgName>
								<orgName type="institution" key="instit2">at Mount Sinai</orgName>
								<address>
									<settlement>New York</settlement>
									<region>NY</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<note type="raw_affiliation"><label>3</label> Windreich Dept. of Artificial Intelligence &amp; Human Health , Icahn School of Medicine at Mount Sinai , New York , NY , USA.</note>
								<orgName type="department">Windreich Dept. of Artificial Intelligence &amp; Human Health</orgName>
								<orgName type="institution">Icahn School of Medicine at Mount Sinai</orgName>
								<address>
									<settlement>New York</settlement>
									<region>NY</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sven</forename><forename type="middle">G</forename><surname>Meuth</surname></persName>
							<affiliation key="aff3">
								<note type="raw_affiliation"><label>4</label> Department of Neurology , Medical Faculty and University Hospital Düsseldorf , Heinrich Heine University Düsseldorf , Düsseldorf , Germany.</note>
								<orgName type="department" key="dep1">Department of Neurology</orgName>
								<orgName type="department" key="dep2">Medical Faculty</orgName>
								<orgName type="institution" key="instit1">University Hospital Düsseldorf</orgName>
								<orgName type="institution" key="instit2">Heinrich Heine University Düsseldorf</orgName>
								<address>
									<settlement>Düsseldorf</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><forename type="first">Lars</forename><surname>Masanneck</surname></persName>
							<email>lars.masanneck@med.uni-duesseldorf.de</email>
							<idno type="ORCID">0000-0003-2496-1415</idno>
							<affiliation key="aff3">
								<note type="raw_affiliation"><label>4</label> Department of Neurology , Medical Faculty and University Hospital Düsseldorf , Heinrich Heine University Düsseldorf , Düsseldorf , Germany.</note>
								<orgName type="department" key="dep1">Department of Neurology</orgName>
								<orgName type="department" key="dep2">Medical Faculty</orgName>
								<orgName type="institution" key="instit1">University Hospital Düsseldorf</orgName>
								<orgName type="institution" key="instit2">Heinrich Heine University Düsseldorf</orgName>
								<address>
									<settlement>Düsseldorf</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<note type="raw_affiliation"><label>5</label> German Society of Digital Medicine e.V. (DGDM) , Berlin , Germany.</note>
								<orgName type="department">German Society of Digital Medicine e.V. (DGDM)</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main" xml:id="_ueTBc39">The three-year evolution of Germany&apos;s Digital Therapeutics reimbursement program and its path forward Check for updates</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">EF8E75001E65833D502FE66A3BE4AF9A</idno>
					<idno type="DOI">10.1038/s41746-024-01137-1</idno>
					<note type="submission">Received: 31 January 2024; Accepted: 10 May 2024;</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.2" ident="GROBID" when="2025-08-31T07:12+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<label type="revision">a91ee48</label>
					<label type="parameters">startPage=-1, endPage=-1, consolidateCitations=2, consolidateHeader=2, consolidateFunders=1, includeRawAffiliations=true, includeRawCitations=true, includeRawCopyrights=true, generateTeiIds=true, generateTeiCoordinates=[all], sentenceSegmentation=true, flavor=null</label>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0" xml:id="_wDXpnsb"><p xml:id="_9xrbHbC"><s xml:id="_kk37hvU">The 2019 German Digital Healthcare Act introduced the Digital Health Application program, known in German as 'Digitale Gesundheitsanwendungen' (DiGA).</s><s xml:id="_UwugWpz">The program has established a pioneering model for integrating Digital Therapeutics (DTx) into a healthcare system with scalable and effective reimbursement strategies.</s><s xml:id="_ZVTMMQJ">To date, the continuous upward trend enabled by this framework has resulted in more than 374,000 DiGA prescriptions, increasingly cementing its role in the German healthcare system.</s><s xml:id="_RPt24JD">This perspective provides a synthesis of the DiGA program's evolution since its inception three years ago, highlighting trends regarding prescriptions and pricing as well as criticisms and identified shortcomings.</s><s xml:id="_pcmbTK6">It further discusses forthcoming legislative amendments, including the anticipated integration of higher-risk medical devices, which have the potential to significantly transform the program.</s><s xml:id="_tNFSTxP">Despite encountering challenges related to effectiveness, evidence requirements, and integration within the healthcare system, the DiGA program continues to evolve and serves as a seminal example for the integration of DTx, offering valuable insights for healthcare systems globally.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<facsimile>
		<surface n="1" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="2" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="3" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="4" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="5" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="6" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="7" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="8" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
	</facsimile>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0" xml:id="_UVUqbzW"><p xml:id="_KcMuSYA"><s xml:id="_Qe3dkdr">The German DiGA program as a nationwide example of a regulated Digital Therapeutics reimbursement pathway Digital Therapeutics (DTx), usually regulated as Software as a Medical Device 1 , are evidence-based digital products which by treating a "disease, disorder, condition, or injury" aim to have "demonstrable positive therapeutic impacts on patient health" 2 .</s><s xml:id="_9qGgnz3">While the concept of leveraging digital solutions for extending the reach of medical practitioners dates back to at least the 1990s <ref type="bibr" target="#b1">3</ref> , healthcare systems worldwide continue to explore effective integration methods for these innovations <ref type="bibr" target="#b2">4,</ref><ref type="bibr" target="#b3">5</ref> .</s></p><p xml:id="_FpBvBDq"><s xml:id="_hxtHJsv">A notable instance of such integration is the 2019 Digital Healthcare Act in Germany <ref type="bibr" target="#b4">6,</ref><ref type="bibr" target="#b5">7</ref> , which established a "Fast-Track" pathway <ref type="bibr" target="#b6">8</ref> for the evaluation and listing of selected DTx in a directory overseen by the German Federal Agency for Drugs and Medical Devices (BfArM) <ref type="bibr" target="#b7">9</ref> .</s><s xml:id="_MUGkK6M">The Digital Health Applications, known in German as 'Digitale Gesundheitsanwendungen' (DiGA), once listed in this directory, automatically become eligible for prescription and reimbursement, benefiting over 74 million individuals covered by Germany's public health insurances, called statutory sickness funds <ref type="bibr" target="#b8">10</ref> .</s><s xml:id="_VPStrbU">At the time of its implementation, this legislation was recognized internationally as the first pathway to reimburse DTx on a large scale <ref type="bibr" target="#b9">11</ref> .</s><s xml:id="_PV8UQcB">Existing manuscripts have examined a variety of facets of the DiGA program, including evidence criteria and reimbursement <ref type="bibr" target="#b10">[12]</ref><ref type="bibr" target="#b11">[13]</ref><ref type="bibr" target="#b12">[14]</ref><ref type="bibr" target="#b13">[15]</ref><ref type="bibr" target="#b14">[16]</ref> , physicians experiences <ref type="bibr" target="#b15">17,</ref><ref type="bibr" target="#b16">18</ref> , and initial experiences across medical and informatic specializations <ref type="bibr" target="#b17">[19]</ref><ref type="bibr" target="#b18">[20]</ref><ref type="bibr" target="#b19">[21]</ref> .</s><s xml:id="_nvXUzDR">This perspective aims to provide a summary of program's development over three years, distilling key learnings and outlining the impending legislative changes that continue to shape this pathway for regulated digital health products.</s></p><p xml:id="_Nwgy4fh"><s xml:id="_wKepZDA">To be eligible for inclusion in the BfArM DiGA directory, DTx products undergo a structured assessment that covers multiple criteria, including both technical and evidence-oriented ones <ref type="bibr" target="#b6">8</ref> .</s><s xml:id="_B387Cuz">The technical criteria mandate functionalities such as security, data protection as well as interoperability and currently require the classification as a lower-risk medical device, either class I or IIa, according to the European Medical Device Regulation (MDR) or Medical Devices Directive (MDD).</s><s xml:id="_TxGTcfk">Beyond these technical prerequisites, DTx applications must conduct comparative studies to demonstrate tangible positive care effects, which are defined in two ways: as a medical benefit, which refers to direct health improvements for patients, or as structural and procedural improvements, indicating patient-relevant enhancements in healthcare delivery.</s></p><p xml:id="_gUjM4Rc"><s xml:id="_52Y3kJp">Furthermore, the current process permits manufacturers to apply for a 'provisional' listing of their DiGA in the directory using preliminary evidence.</s><s xml:id="_b3RUwJn">Once provisionally listed, manufacturers have a twelve-month period, conditionally extendable, to produce high-quality evidence.</s><s xml:id="_tYsPV6h">During this time, the DiGA can be prescribed and is subject to conditional reimbursement (see Fig. <ref type="figure" target="#fig_0">1</ref>).</s><s xml:id="_g68z97P">For the first year after listing, manufacturers have the flexibility to set their own prices within maximum limits determined by predefined rules, which consider the prices of comparable DiGAs.</s><s xml:id="_QHbV594">Under the agreement between insurers and manufacturers <ref type="bibr" target="#b20">22</ref> , comparable DiGAs are categorized by their indication group and intended benefit, facilitating the establishment of maximum price reimbursement thresholds for each category that includes at least two DiGAs.</s><s xml:id="_duNTg7W">In the first year of a DiGA's listing, these maximum reimbursement limits are utilized as reference points for pricing, contingent upon the DiGA's prescription volume.</s><s xml:id="_SV3zUXU">For DiGAs that pioneer their indication group, target rare diseases, or leverage sophisticated artificial intelligence, the standard pricing rules are modified, further incentivizing innovation and the addressing of unmet medical needs.</s><s xml:id="_xgHHDaA">Concurrently, negotiations between the manufacturer and the public insurances known as sickness funds take place to establish the price for the period following the initial 12 months, with these discussions also considering the established maximum reimbursement price.</s><s xml:id="_VfXxVMD">In cases where a price agreement is not reached, arbitration is used, with any determined prices applied retroactively from the 13th month onwards.</s></p><p xml:id="_5ZW7AJ3"><s xml:id="_vzJ3Unw">The pathway of preliminary DiGA listing is comparable to the already existing pathway of 'new examination and treatment methods', in German 'Neue Untersuchungs-und Behandlungsmethoden' (NUB), pathway, which allows for reimbursement of new examination and treatment methods that are not jet covered by the German Diagnosis Related Groups system for reimbursement.</s><s xml:id="_beExFN5">However, the provisional DiGA listing is strategically oriented to bridge the gap between innovation and evidence, while the NUB system aims to bridge the gap between the introduction of new examination and treatment methods and their formal integration into the reimbursement system.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_nJqZqRw">Three-year trends in DiGA applications since initiation of the program</head><p xml:id="_fRcgPJX"><s xml:id="_BVKFuHw">As of January 16th, 2024, the BfArM maintained directory listed 53 DiGAs, comprising 29 permanent listings and 24 provisional listings.</s><s xml:id="_5SRgj2U">Since its start in September 2020, six provisionally listed DiGAs have been removed from the directory, either due to failure in providing the required evidence or at the manufacturer's request (see Fig. <ref type="figure">2</ref>).</s><s xml:id="_AUuvUsG">The majority of DiGAs are available as mobile applications (34), often paired with a web application (9), while standalone web applications are less common (19).</s><s xml:id="_eKGWwwx">Over the three years since the program's inception until the end of September 2023, approximately 374,000 DiGA prescriptions have been activated for patient use, reflecting an increasing trend and costing the German public health insurances approximately 113 million € <ref type="bibr" target="#b21">23</ref> .</s></p><p xml:id="_nzSHh8t"><s xml:id="_naG3983">The directory predominantly features DTx for mental health conditions (25), followed by musculoskeletal disorders (8), neurological diseases (6), and endocrinological conditions ( <ref type="formula">6</ref>), reflecting broader trends in DTx research <ref type="bibr" target="#b22">24</ref> .</s><s xml:id="_qhb973c">Less common, yet represented, indication fields currently featured are gynecological diseases (4), oncology (3), diseases of the auditory system (2), cardiovascular diseases (2), respiratory diseases (1), urological diseases (1), lifestyle conditions (1), and diseases of the gastrointestinal tract <ref type="url" target="https://doi.org/10.1038/s41746-024-01137-1">https://doi.org/10.1038/s41746-024-01137-1</ref></s></p><p xml:id="_fDaMfHn"><s xml:id="_g4CGWMq">(1) (7 DiGAs are listed in two separate indication groups).</s><s xml:id="_7cZZan6">Initially, the directory focused mainly on psychiatric and neurological disorders, but over time, the range of covered indications has shown a diversifying trend (see Fig. <ref type="figure">2</ref>).</s><s xml:id="_YRFCEF3">Interestingly, in terms of yearly prescription percentages, psychiatry leads, followed by endocrinology, orthopedics and diseases of the auditory system (see Fig. <ref type="figure">3</ref>).</s></p><p xml:id="_633McGM"><s xml:id="_4sjXjjc">Most DiGAs offer a combination of lifestyle or condition-specific advice, cognitive behavioral therapy elements, informational features, tracking capabilities, and physiotherapy programs.</s><s xml:id="_6JVDEv8">Only a few utilize external sensors although the addition of external sensors to a DiGA has been permitted since the introduction of the DiGA pathway <ref type="bibr" target="#b23">25</ref> .</s><s xml:id="_XMznx7q">A notable trend is that most DiGA users are female, particularly in oncology, neurology, endocrinology, and gastroenterology applications.</s><s xml:id="_hSpb3nc">This reflects the broader pattern of women more frequently taking part in DTx trials <ref type="bibr" target="#b24">26</ref> and more often engaging in medical care services <ref type="bibr" target="#b25">27</ref> .</s><s xml:id="_nWd2Pwc">Recent findings in the US reveal that women engage more with health digitalization, seen in their greater use of wearables and openness to health data sharing <ref type="bibr" target="#b26">28</ref> .</s><s xml:id="_yqEMjg7">While this may explain the higher DiGA usage among women, understanding the underlying reasons and addressing the imbalance requires further research.</s></p><p xml:id="_AShx4qC"><s xml:id="_hU2u6Rc">In 2023, the median age across all indication groups spanned from 41 to 66 years <ref type="bibr" target="#b21">23</ref> .</s><s xml:id="_jBVEAWU">Furthermore, most applications are class I medical devices, with only two classified as class IIa.</s><s xml:id="_HXWzyJq">Notably, five manufacturers list multiple DiGAs, with the highest number being seven from one manufacturer (GAIA AG), typically within similar indication areas (see Suppl. Figure <ref type="figure" target="#fig_0">1</ref>).</s></p><p xml:id="_fMNrm32"><s xml:id="_ma8tG46">The majority of permanently listed DiGAs are prescribed for a period of 90 days (28 of 29, with the notable exception of "Mawendo", offering a one-time license), which is likely preferred due to its alignment with the quarterly billing cycle in German medical practices.</s><s xml:id="_Ej5X74g">After the initial 90 days of prescription, four DiGAs are offered for a discounted subsequent prescription.</s><s xml:id="_D7JevJv">For permanently listed DiGAs with a 90-day prescription window and concluded negotiations with the sickness funds (n = 20) the mean cost for manufacturer-set prices for initial prescription is 465.42€, while for negotiated final prices it is 220.79€</s><s xml:id="_sNJMH5V">(see Fig. <ref type="figure" target="#fig_2">4</ref>).</s><s xml:id="_Un2Avvy">Although DiGA prices have been reported to steadily increase since their initial implementation <ref type="bibr" target="#b21">23</ref> , there <ref type="url" target="https://doi.org/10.1038/s41746-024-01137-1">https://doi.org/10.1038/s41746-024-01137-1</ref></s><s xml:id="_pVXMtTb">c Proportion of female users for each indication group in 2022 and 2023.</s><s xml:id="_Rewes4G">All three subplots are based on the data from the official DiGA reports by the sickness fund association (GKV Spitzenverband) <ref type="bibr" target="#b21">23,</ref><ref type="bibr" target="#b39">41,</ref><ref type="bibr" target="#b40">42</ref> .</s><s xml:id="_bNgPJHX">The data cut-off date is September 20 th of the respective years.</s></p><p xml:id="_NuzFVzW"><s xml:id="_5Re8vKh"><ref type="url" target="https://doi.org/10.1038/s41746-024-01137-1">https://doi.org/10.1038/s41746-024-01137-1</ref></s><s xml:id="_fa8UZ4R">has been a shift towards more stable pricing, with a noticeable plateau beginning in 2023 at median of 540.00€ for manufacturer-set prices (see Suppl. Figure <ref type="figure">2</ref>).</s><s xml:id="_QueFmuv">This might be attributed to legislative changes in 2022 that imposed constraints on manufacturer-set prices.</s><s xml:id="_A3bd5bm">It should be highlighted that there exists a significant positive correlation between the initial prices set by manufacturers and the prices established post-negotiation (Pearson correlation coefficient of 0.79, P value &lt; 0.001).</s><s xml:id="_te4WqeC">Nonetheless, the absolute difference in negotiated prices, ranging from the highest at €243.00 to the lowest at €189.00, is relatively modest.</s><s xml:id="_JujxK4y">Only one DiGA ("Kalmeda") negotiated a higher permanent listing price than initially set by the manufacturers.</s><s xml:id="_KnHqdE2">Although, it is worth mentioning that the negotiated price is still below the overall average.</s><s xml:id="_9NZYzqm">The remaining 19 DiGAs negotiated a lower permanent price.</s><s xml:id="_QN5SxjQ">While there is currently only one permanently listed DiGA with a one-time license, this appears to be a more common pricing model in more recently provisionally added DiGAs (5 of 24).</s><s xml:id="_fsDKHyv">The analysis of the additional devices (such as sensors) used in DiGAs, along with their corresponding medical device classifications and application platforms (web-based, mobile, or both) reveals no evident trend in the years following the program's initiation.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_x5Uwwaj">Criticisms of the DiGA program and current legislative changes aiming to reshape it</head><p xml:id="_x5ybJmM"><s xml:id="_sYxeWAZ">Throughout its three-year existence, the DiGA directory has seen both successes and controversies, exemplified by the ongoing discussions between public insurance companies and manufacturers.</s><s xml:id="_hNgmynB">The reimbursing German sickness funds have expressed concerns over what they perceive as low effectiveness and insufficient evidence for DiGAs <ref type="bibr" target="#b21">23</ref> , especially those provisionally listed in the directory, a sentiment echoed in some scientific literature <ref type="bibr" target="#b27">29</ref> .</s><s xml:id="_cq5uDSs">On the other hand, DiGA manufacturers have highlighted challenges related to delayed patient access to applications, with a survey of 17 manufacturers indicating an average waiting time of 13 days postprescription submission to the health insurance <ref type="bibr" target="#b28">30</ref> .</s><s xml:id="_5JBgzzR">Manufacturers claim that this delay compromises the quick DiGA access for patients that is vital for treatment efficacy and acceptance.</s><s xml:id="_XwRYDME">Additionally, while alternative pricing models based on patient application usage or real-world effects are explicitly allowed in the regulation <ref type="bibr" target="#b6">8</ref> , none of the DTx currently listed in the DiGA directory utilizes models such as treatment success-based reimbursement.</s><s xml:id="_V5g4XDX">Only the application "Smoke Free" offers a 7-day prescription-free start phase of all app functionalities.</s><s xml:id="_zfB9kuU">In general, the potential of DiGAs in collecting real-world data (RWD) and real-world evidence (RWE) for health technology assessment or flexible pricing remains largely untapped as of today <ref type="bibr" target="#b11">13,</ref><ref type="bibr" target="#b13">15</ref> .</s><s xml:id="_wtnWKea">This is despite the fact that DTx such as DiGAs, as digital tools, are uniquely equipped to gather patient-reported outcome measures (PROMs) and usage or performance data with minimal additional effort.</s></p><p xml:id="_ku5zzns"><s xml:id="_m7uftFB">Other points of critique include the fact that initial analyses reveal mixed app-store reviews <ref type="bibr" target="#b29">31</ref> and emerging data in specific areas like rheumatology indicate limited adherence to DTx and varying user satisfaction <ref type="bibr" target="#b17">19</ref> .</s><s xml:id="_MhsxFQ3">Furthermore, a comprehensive analysis conducted by a leading German sickness fund, which combined routine data with a survey of over 1700 patients who used a DiGA, paints an ambivalent picture.</s><s xml:id="_kCQAzm5">While satisfaction with DiGAs among patients was high, they noted limited impact on the disease course and treatment outcomes, underlining the need to track efficacy for these DTx.</s><s xml:id="_U5b2RAG">A common concern was the lack of adequate information about the DTx, especially from prescribing physicians <ref type="bibr" target="#b15">17</ref> .</s></p><p xml:id="_bPDa5TS"><s xml:id="_DVW2JxE">The recent passage of two new laws by the German Bundestag, the Digital Act <ref type="bibr" target="#b30">32</ref> and the Health Data Use Act <ref type="bibr" target="#b31">33</ref> , is set to significantly advance digitalization in the German healthcare system.</s><s xml:id="_jc6vSA7">Both laws will also bring fundamental changes to the DiGA program.</s><s xml:id="_4992n8Q">Notably, future DiGAs can also include higher-risk medical devices, namely those classified as class IIb of MDR.</s><s xml:id="_QNnjg7a">This expansion, addressing previous criticisms of the program's limited initial approach <ref type="bibr" target="#b9">11</ref> , paves the way for more complex telemonitoring or remote monitoring approaches to be integrated into DTx using the DiGA pathway.</s><s xml:id="_TUa5xud">However, in line with these changes, the legislator is imposing stricter evidence requirements for these higher-risk devices, such as the need for prospective comparative studies.</s><s xml:id="_2zWYhrZ">Importantly, the option of 'provisional listing' for IIb devices, based solely on preliminary evidence, will no longer be available <ref type="bibr" target="#b30">32</ref> .</s></p><p xml:id="_RNC6ujR"><s xml:id="_CDtq5gZ">Another key forthcoming change in the DiGA program is the alteration of reimbursement methods, as from 2026 on at least 20% of a DiGA's reimbursement price will be contingent upon success measures.</s><s xml:id="_RXvvBMm">While these specific measures are still to be defined by the BfArM, likely candidates may include adherence rates, user satisfaction, or other PROMs.</s><s xml:id="_QZVymVj">Depending on the measures that will be assessed, this change could lead to an unprecedented mandatory generation of DiGA-specific RWD <ref type="bibr" target="#b11">13</ref> via PROMS and similar instruments, offering insights into actual usage and effectiveness of these DTx.</s><s xml:id="_Ug7NrQn">This development is poised to contribute significantly to the ongoing discourse on value-based pricing, focusing on the balance of cost and effectiveness <ref type="bibr" target="#b14">16</ref> .</s><s xml:id="_DRaS5bZ">As RWD collection will subsequently be a feature embedded into all DiGAs, the further usage of RWE <ref type="bibr" target="#b11">13</ref> for assessment of DiGAs appears also more likely.</s></p><p xml:id="_8dvB66r"><s xml:id="_TPSmKBq">Additionally, an initial proposal for a 14-day test phase, allowing patients to try a DiGA and opt-out without incurring reimbursement costs, was considered in the early drafts of the new legislation but ultimately not adopted in the final version <ref type="bibr" target="#b30">32,</ref><ref type="bibr" target="#b32">34</ref> .</s><s xml:id="_8dkg3W5">Such concepts generally raise the question, whether DTx should be treated differently than other therapeutics such as pharmaceutical or surgical interventions, where test phases would be impossible to realize.</s></p><p xml:id="_AbA2UAd"><s xml:id="_X2JU9Et">Additional significant changes have been incorporated into the final legislation with the aim to streamline DiGA access and integration within Germany's digital health ecosystem.</s><s xml:id="_NJdRUGv">One such change mandates that sickness funds must provide access to DiGAs within a maximum of two days.</s><s xml:id="_wFCz2C6">Moreover, there is an emphasis on enhancing DiGA integration into the broader digital health infrastructure, which includes a new requirement for interoperability with the electronic health record system starting later in 2024.</s><s xml:id="_7esYm38">This system, despite its current infrequent usage, is set to become more widely adopted as it will be rolled out as an opt-out solution for all publicly insured individuals in Germany by the beginning of 2025 <ref type="bibr" target="#b30">32,</ref><ref type="bibr" target="#b32">34</ref> .</s></p><p xml:id="_qF7d3QP"><s xml:id="_prSRjVd">Although more than half of general practitioners in Germany have already prescribed DiGAs <ref type="bibr" target="#b15">17</ref> , recent research has further highlighted the critical importance of digital health literacy and the affinity of practicing doctors towards digital technologies for the success of digital health adoption <ref type="bibr" target="#b33">35</ref> .</s><s xml:id="_WhUkZcU">This research further points to the essential need for enhancing public awareness and developing comprehensive digital education programs for physicians <ref type="bibr" target="#b34">36</ref> .</s><s xml:id="_Dxcn9jZ">As the DiGA-manufacturing companies rapidly expand their workforce <ref type="bibr" target="#b28">30</ref> , it is likely that currently often lacking sales and distribution networks will be established and consequently further contribute to public and healthcare provider awareness.</s></p><p xml:id="_kZktWfZ"><s xml:id="_etvQ4YC">While recent evolutions in the DiGA program are designed to address many existing criticisms (see Table <ref type="table" target="#tab_0">1</ref> for key learnings and legislative changes), certain issues remain unaddressed.</s><s xml:id="_8jua6da">The dynamic nature of DiGAs (and generally all DTx), as updatable software products, presents challenges to the current methods of evidence generation and health technology assessment, which may not be ideally suited for such evolving products <ref type="bibr" target="#b12">14</ref> .</s><s xml:id="_c76e2Tr">Furthermore, the lack of international cooperation and standardized frameworks not only limits the transferability of innovations across borders but consequently also leads to economic inefficiencies <ref type="bibr" target="#b35">37</ref> .</s><s xml:id="_xSD4Uqw">While there is still much to be done in this area, initial promising efforts to harmonize standards such as the European Taskforce for Harmonised Evaluations of Digital Medical Devices <ref type="bibr" target="#b36">38,</ref><ref type="bibr" target="#b37">39</ref> , led by the French Ministry of Health and Prevention and coordinated by EIT Health, should be supported and encouraged to ensure the international transferability of DTx and other digital tools.</s></p><p xml:id="_Td2tQXE"><s xml:id="_EnGueRu">Meanwhile, the DiGA program, with its ongoing revisions and updates, serves as a notable example of how DTx can be successfully integrated into a healthcare system that has historically been slow to adopt digitalization <ref type="bibr" target="#b38">40</ref> .</s><s xml:id="_WC4JTJu">Indeed, the DiGA program's core principles are being replicated in other healthcare settings, most notably by France, which in 2023 introduced a comparable "Fast-Track" initiative for DTx and telemedicine applications, notably across all MDR risk classes <ref type="bibr" target="#b2">4</ref> .</s><s xml:id="_vMdHHJD">Belgium, with a different reimbursement system, also introduced a 'Fast-Track' for DTx, There appears to be a discrepancy between DiGA pricing and their clinical benefits, indicating that the actual success of a DiGA is not adequately reflected in its cost.</s></p><p xml:id="_G7YZ52c"><s xml:id="_u2XGYzP">Starting in 2026, a minimum of 20% of a DiGA's reimbursement price will be linked to the achievement of (yet to be defined) success metrics.</s></p><p xml:id="_EG4akqc"><s xml:id="_7XQH73V">Patient access to prescribed DiGA is often delayed, highlighting inefficiencies in delivery systems.</s></p><p xml:id="_JXWQrg8"><s xml:id="_n7ExZGg">Health insurances will be mandated to provide access to DiGA within two days of prescription, aiming to reduce patient waiting times.</s></p><p xml:id="_wUzUTFQ"><s xml:id="_RSkDEG7">DiGA integration into the broader German healthcare system is currently insufficient.</s></p><p xml:id="_kWrjD2p"><s xml:id="_pyjPpF9">Increased requirements for DiGA integration into electronic health records systems are anticipated, with an emphasis on interoperability.</s></p><p xml:id="_56SYvWb"><s xml:id="_QvM7jKG">A significant number of users discontinue using their prescribed DiGA shortly after initial registration or first use, suggesting issues with user engagement or application efficacy.</s></p><p xml:id="_SmdRDWq"><s xml:id="_8BhYkYR">A proposed 14-day trial period for DiGA was included in the first versions of the new legislation, but was not included in the final draft.</s></p><p xml:id="_xW2BKnE"><s xml:id="_XShyvaK"><ref type="url" target="https://doi.org/10.1038/s41746-024-01137-1">https://doi.org/10.1038/s41746-024-01137-1</ref></s></p><p xml:id="_saRn7p8"><s xml:id="_R8JJexQ">which builds on a pyramidal assessment of technical and evidence prerequisites <ref type="bibr" target="#b2">4</ref> .</s><s xml:id="_6FVcWaH">In summary, the use of DTx, as illustrated by the DiGA case, faces multi-level challenges.</s><s xml:id="_8TjWHuc">Physicians need to integrate DTx, PROMs, and monitoring into their routines effectively, while more research is required to enhance patient adherence to DTx and to understand the observed usage disparities across genders.</s><s xml:id="_yTVcSF7">The collaboration between payers and manufacturers is essential for DTx success, particularly as this nascent market and emerging field continues to develop its processes and priorities.</s></p><p xml:id="_rBhpuNR"><s xml:id="_g7TUE5a">The recent adjustments to the German DiGA framework signal a promising shift aiming at greater impact for patients and underline the adaptive process necessary when introducing piloting legislature.</s><s xml:id="_Ez66GSH">By incorporating higher-risk devices and mandating the collection of RWD, the German DiGA program is poised for significant evolution.</s><s xml:id="_5kkjBgx">It thus continues to stand as a leading model for implementing DTx at scale, providing globally valuable insights into the challenges, opportunities, and potential pitfalls encountered along the way.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1 |</head><label>1</label><figDesc><div><p xml:id="_gY7tAKg"><s xml:id="_crqvne4">Fig. 1 | Current DiGA pathway and upcoming regulatory changes.</s><s xml:id="_HCnEvQ4">Flowchart of the Digital Health Application (DiGA) "Fast-Track" approval process, illustrating the steps from criteria checks to admission into the DiGA directory.</s><s xml:id="_q47jFrN">Different pathways depending on the current evidence for the product and the class of the medical device are shown, with upcoming changes based on the new Digital Act depicted in blue.</s></p></div></figDesc><graphic coords="2,90.40,399.71,390.04,241.72" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 2 | 1 Fig. 3 |</head><label>213</label><figDesc><div><p xml:id="_UwYnd3z"><s xml:id="_XWbGmBU">Fig. 2 | Number of DiGAs in different stages of the regulatory process and indication fields over time.</s><s xml:id="_RJrb9rm">a Stacked area chart showing the total number of Digital Health Applications (DiGAs) listed over time, categorized by listing status.</s><s xml:id="_3HHBT34">The categories include provisional, permanent, and discontinued listings.</s><s xml:id="_GAmZt2j">b Stacked area chart showing the percentage of all DiGAs for all indication group over time, while each DiGA can count into multiple indication groups.</s><s xml:id="_TYrVucv">All discontinued DiGAs are not included.</s><s xml:id="_q8KbNUn">Both graphs depict the listings from the directory's initiation in 2020 to January 16 th , 2024.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Fig. 4 |</head><label>4</label><figDesc><div><p xml:id="_GnTDcZA"><s xml:id="_9EcKVv7">Fig. 4 | Initial manufacturer-set and final post-negotiation prices of permanently listed DiGAs.</s><s xml:id="_rDcGxqN">a Scatter plot illustrating the relationship between initial listing price and post-negotiation prices of 20 permanently listed Digital Health Applications (DiGAs) after price negotiation and with a 90-day prescription window across different listing years (at January 16th, 2024).</s><s xml:id="_suAzPJ6">Each point represents an individual DiGA, with the color indicating the year of initial listing.</s><s xml:id="_qf7krtt">The x-axis denotes the initial listing price in euros set by the manufacturers, while the y-axis shows the negotiated permanent listing price in euros.</s><s xml:id="_CG2NtHk">DiGA prescribed via a one-time license are excluded.</s><s xml:id="_96vtyju">b Boxplots showing the variability of prices before and after price negotiation for the indication group psychiatry (n = 11) for DiGAs which completed the entire process.</s><s xml:id="_ybQgHVj">DiGAs prescribed via a one-time license are excluded.</s><s xml:id="_X9hzZMm">All other indication groups had a count of less than 4 DiGAs.</s><s xml:id="_h3Qybvm">DiGA manufacturers are within certain rules allowed to set a price for the first 12 months the app is listed in the directory, from the 13th month on a price negotiated between sickness funds and manufacturer applies.</s><s xml:id="_QvNXXwp">The boxplot center line indicates the median, box limits indicate upper and lower quartiles, whiskers indicate 1.5x interquartile range.</s><s xml:id="_muSxQHm">The black point indicates an outlier.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 |</head><label>1</label><figDesc><div><p xml:id="_JGDjvFb"><s xml:id="_NzhW9Bn">Selected key learnings and future legislative changes addressing these Restricting approvals to only medical devices of class I or IIa narrows the range of potential DiGA applications.</s><s xml:id="_yB6n5VD">Future regulations will permit class IIb medical devices to qualify as DiGA, albeit with stricter requirements, such as the necessity for demonstrated medical benefits and no accelerated track.</s></p></div></figDesc><table><row><cell>Key Learning</cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_0"><p xml:id="_8UFd3N2"><s xml:id="_zyV6fa5">npj Digital Medicine | (2024) 7:139</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_1"><p xml:id="_EXP8cW8"><s xml:id="_P56BPGr">© The Author(s) 2024 https://doi.org/10.1038/s41746-024-01137-1</s></p></note>
		</body>
		<back>

			<div type="acknowledgement">
<div><head xml:id="_2FzMaH8">Acknowledgements</head><p xml:id="_FMGv6gb"><s xml:id="_U3NgAP9">This research was partially funded by support of the <rs type="funder">HPI Research School on Data Science and Engineering</rs> to LS. LM's research is partially funded by the <rs type="funder">Deutsche Forschungsgemeinschaft (DFG, German Research Foundation</rs>) -<rs type="grantNumber">493659010</rs>.</s></p></div>
			</div>
			<div type="funding">
<div><head xml:id="_EkfUNGK">Funding</head><p xml:id="_TnHC7gr"><s xml:id="_JrZjCKn">Open Access funding enabled and organized by <rs type="funder">Projekt DEAL</rs>.</s></p></div>
			</div>
			<listOrg type="funding">
				<org type="funding" xml:id="_tkFvHpx">
					<idno type="grant-number">493659010</idno>
				</org>
			</listOrg>

			<div type="availability">
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_kFMzMkz">Data availability</head><p xml:id="_BfhdeHF"><s xml:id="_HrPy62m">The data underlying this work are from public sources, explicitly the DiGA directory <ref type="bibr" target="#b7">9</ref> , the DiGA reports by the sickness fund association <ref type="bibr" target="#b21">23,</ref><ref type="bibr" target="#b39">41,</ref><ref type="bibr" target="#b40">42</ref> and public data aggregated in the "DiGA Analyzer" by _fbeta GmbH <ref type="bibr" target="#b41">43</ref> .</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_r3rS7ht">Code availability</head><p xml:id="_XnwXHQe"><s xml:id="_pSNeuEu">Final data and code used for designing the graphs can be accessed in the following GitHub repository: <ref type="url" target="https://github.com/Linea-code/DiGA_analysis_figures">https://github.com/Linea-code/DiGA_  analysis_figures</ref>.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_vNZvkSy">Author contributions</head><p xml:id="_TQTjgau"><s xml:id="_gFuF4g5">L.S. and L.M. conducted the data collection and analysis and wrote the initial draft of the manuscript.</s><s xml:id="_4bB7CfT">L.S., M.P. and L.M. drafted the study and analysis concept.</s><s xml:id="_meCTAnx">B.Y.R. and S.G.M. reviewed the study draft and contributed to the analysis plan.</s><s xml:id="_6ks3SnU">All authors interpreted the results, contributed to manuscript preparation and critical revisions.</s><s xml:id="_7bxMvTQ">All authors have read and approved the manuscript.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_uEm234f">Competing interests</head><p xml:id="_AyMxgsm"><s xml:id="_Z7wzYeh">LS reports no conflicts of interest, MP reports no conflict of interest related to this study, BYR reports no conflict of interest related to this study, SGM reports no conflict of interest related to the content of this study, LM declares that he serves as the Chairman of the German Society for Digital Medicine.</s><s xml:id="_cye25nZ">He reports no further conflicts of interest related to this study.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_hJepNUQ">Additional information</head><p xml:id="_YBANQeT"><s xml:id="_svFPBQm">Supplementary information The online version contains supplementary material available at <ref type="url" target="https://doi.org/10.1038/s41746-024-01137-1">https://doi.org/10.1038/s41746-024-01137-1</ref>.</s></p><p xml:id="_MJZshYr"><s xml:id="_bC3XeVM">Correspondence and requests for materials should be addressed to Lars Masanneck.</s></p><p xml:id="_43tnyb2"><s xml:id="_UqUPtTX">Reprints and permissions information is available at <ref type="url" target="http://www.nature.com/reprints">http://www.nature.com/reprints</ref></s><s xml:id="_H5PcwxV">Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</s></p><p xml:id="_NaaS698"><s xml:id="_Vq7ucHq">Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.</s><s xml:id="_TFjeH52">The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material.</s><s xml:id="_fcczmER">If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.</s><s xml:id="_jRHv978">To view a copy of this licence, visit <ref type="url" target="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ref>.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main" xml:id="_AYwCp5w">Digital therapeutics (DTx)</title>
		<author>
			<persName><forename type="first">D</forename><surname>Fürstenau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gersch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Schreiter</surname></persName>
		</author>
		<idno type="DOI">10.1007/s12599-023-00804-z</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_GPtqVZE">Bus. Inf. Syst. Eng</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="349" to="360" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Fürstenau, D., Gersch, M. &amp; Schreiter, S. Digital therapeutics (DTx). Bus. Inf. Syst. Eng. 65, 349-360 (2023).</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main" xml:id="_z6bYfEQ">The emerging world of digital therapeutics</title>
		<author>
			<persName><forename type="first">S</forename><surname>Makin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_phuvQBA">Nature</title>
		<imprint>
			<biblScope unit="volume">573</biblScope>
			<biblScope unit="page" from="106" to="S109" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Makin, S. The emerging world of digital therapeutics. Nature 573, S106-S109 (2019).</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main" xml:id="_rKmX8zz">Digital Health Reimbursement Strategies of 8 European Countries and Israel: Scoping Review and Policy Mapping</title>
		<author>
			<persName><surname>Kessel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_UwDc7Ey">JMIR MHealth UHealth</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">49003</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kessel et al. Digital Health Reimbursement Strategies of 8 European Countries and Israel: Scoping Review and Policy Mapping. JMIR MHealth UHealth 11, e49003 (2023).</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main" xml:id="_pfMfnFB">Introduction of digital therapeutics</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Hong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Wasden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Han</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cmpb.2021.106319</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_bNRwPQB">Comput. Methods Prog. Biomed</title>
		<imprint>
			<biblScope unit="volume">209</biblScope>
			<biblScope unit="page">106319</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hong, J. S., Wasden, C. &amp; Han, D. H. Introduction of digital therapeutics. Comput. Methods Prog. Biomed. 209, 106319 (2021).</note>
</biblStruct>

<biblStruct xml:id="b4">
	<monogr>
		<idno type="DOI">10.4324/b23291</idno>
		<ptr target="https://www.bundesgesundheitsministerium.de/en/digital-healthcare-act" />
		<title level="m" xml:id="_hP7pxYg">Driving the digital transformation of Germany&apos;s healthcare system for the good of patients</title>
		<imprint>
			<date type="published" when="2024-01-03">January 3, 2024</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Driving the digital transformation of Germany&apos;s healthcare system for the good of patients. https://www.bundesgesundheitsministerium. de/en/digital-healthcare-act (Accessed January 3, 2024).</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main" xml:id="_arsdCjr">Digitale-Versorgung-Gesetz -DVG)</title>
		<idno type="DOI">10.1007/s12312-019-0650-1</idno>
	</analytic>
	<monogr>
		<title level="m" xml:id="_kXGV5ty">Gesetz für eine bessere Versorgung durch Digitalisierung und Innovation</title>
		<imprint>
			<date type="published" when="2019">2019</date>
			<biblScope unit="page">2562</biblScope>
		</imprint>
	</monogr>
	<note type="raw_reference">Gesetz für eine bessere Versorgung durch Digitalisierung und Innovation (Digitale-Versorgung-Gesetz -DVG). Bundesgesetzblatt Teil I 2562 (2019).</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title/>
		<idno type="DOI">10.9785/gesr-2020-191103</idno>
		<ptr target="https://www.bfarm.de/SharedDocs/Downloads/EN/MedicalDevices/DiGA_Guide.pdf?__blob=publicationFile" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_U9xVQSq">BfArM. DiGA Guide</title>
		<imprint>
			<date type="published" when="2024-01-16">January 16, 2024</date>
		</imprint>
	</monogr>
	<note>Version 3.5</note>
	<note type="raw_reference">BfArM. DiGA Guide (Version 3.5). https://www.bfarm.de/ SharedDocs/Downloads/EN/MedicalDevices/DiGA_Guide.pdf? __blob=publicationFile (Accessed January 16, 2024).</note>
</biblStruct>

<biblStruct xml:id="b7">
	<monogr>
		<idno type="DOI">10.9785/gesr-2020-191103</idno>
		<ptr target="https://diga.bfarm.de/de/verzeichnis" />
		<title level="m" xml:id="_pdqMgwX">DiGA-Verzeichnis</title>
		<imprint>
			<date type="published" when="2024-01-25">January 25, 2024</date>
		</imprint>
	</monogr>
	<note type="raw_reference">DiGA-Verzeichnis. https://diga.bfarm.de/de/verzeichnis (Accessed January 25, 2024).</note>
</biblStruct>

<biblStruct xml:id="b8">
	<monogr>
		<ptr target="https://www.vdek.com/presse/daten/b_versicherte.html" />
		<title level="m" xml:id="_NED5aRX">Daten zum Gesundheitswesen: Versicherte</title>
		<imprint>
			<date type="published" when="2024-01-06">January 6, 2024</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Daten zum Gesundheitswesen: Versicherte. https://www.vdek.com/ presse/daten/b_versicherte.html (Accessed January 6, 2024).</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main" xml:id="_vDeXa94">Germany&apos;s digital health reforms in the COVID-19 era: lessons and opportunities for other countries</title>
		<author>
			<persName><forename type="first">S</forename><surname>Gerke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Stern</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Minssen</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41746-020-0306-7</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_pk33Mrz">NPJ Digit. Med</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">94</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Gerke, S., Stern, A. D. &amp; Minssen, T. Germany&apos;s digital health reforms in the COVID-19 era: lessons and opportunities for other countries. NPJ Digit. Med. 3, 94 (2020).</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main" xml:id="_KfVu9m8">Evidence requirements of permanently listed digital health applications (DiGA) and their implementation in the German DiGA directory: an analysis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Mäder</surname></persName>
		</author>
		<idno type="DOI">10.1186/s12913-023-09287-w</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ChK8zk6">BMC Health Serv. Res</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page">369</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Mäder, M. et al. Evidence requirements of permanently listed digital health applications (DiGA) and their implementation in the German DiGA directory: an analysis. BMC Health Serv. Res 23, 369 (2023).</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main" xml:id="_33JqWAE">Advancing digital health applications: priorities for innovation in real-world evidence generation</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Stern</surname></persName>
		</author>
		<idno type="DOI">10.1016/s2589-7500(21)00292-2</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_waKWH29">Lancet Digit. Health</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="200" to="e206" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Stern, A. D. et al. Advancing digital health applications: priorities for innovation in real-world evidence generation. Lancet Digit. Health 4, e200-e206 (2022).</note>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main" xml:id="_k2NGHd7">Dynamic HTA for digital health solutions: opportunities and challenges for patientcentered evaluation</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Brönneke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Herr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Reif</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Stern</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_vnRh9tD">Int. J. Technol. Assess. Health Care</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page">72</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Brönneke, J. B., Herr, A., Reif, S. &amp; Stern, A. D. Dynamic HTA for digital health solutions: opportunities and challenges for patient- centered evaluation. Int. J. Technol. Assess. Health Care 39, e72 (2023).</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main" xml:id="_Wy9eXPV">Benefit Assessment and Reimbursement of Digital Health Applications: Concepts for Setting Up a New System for Public Coverage</title>
		<author>
			<persName><forename type="first">H</forename><surname>Lantzsch</surname></persName>
		</author>
		<idno type="DOI">10.3389/fpubh.2022.832870</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_cs67EGN">Front. Public Health</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lantzsch, H. et al. Benefit Assessment and Reimbursement of Digital Health Applications: Concepts for Setting Up a New System for Public Coverage. Front. Public Health 10, (2022).</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main" xml:id="_FVCQdXA">Market access and value-based pricing of digital health applications in Germany</title>
		<author>
			<persName><forename type="first">D</forename><surname>Gensorowsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Witte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Batram</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Greiner</surname></persName>
		</author>
		<idno type="DOI">10.1186/s12962-022-00359-y</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_FB6VGTy">Cost. Eff. Resour. Alloc</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page">25</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Gensorowsky, D., Witte, J., Batram, M. &amp; Greiner, W. Market access and value-based pricing of digital health applications in Germany. Cost. Eff. Resour. Alloc. 20, 25 (2022).</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<author>
			<persName><forename type="first">A</forename><surname>Rumbler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>L'hoest</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Arndt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Janke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Marschall</surname></persName>
		</author>
		<idno type="DOI">10.30433/ePMVF.2024.001</idno>
		<ptr target="https://doi.org/10.30433/ePMVF.2024.001" />
	</analytic>
	<monogr>
		<title level="m" xml:id="_UQMYHfM">Digitale Gesundheitsanwendungen (DiGA) -Mehr Transparenz für mehr Akzeptanz</title>
		<title level="s" xml:id="_EUFx8RR">BARMER Inst. Für Gesundheitssystemforschung Bifg</title>
		<imprint/>
	</monogr>
	<note type="raw_reference">Rumbler, A., L&apos;hoest, H., Arndt, K. M., Janke, A. L. &amp; Marschall, U. Digitale Gesundheitsanwendungen (DiGA) -Mehr Transparenz für mehr Akzeptanz. BARMER Inst. Für Gesundheitssystemforschung Bifg https://doi.org/10.30433/ePMVF.2024.001.</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main" xml:id="_qnWSBT6">Two years of approved digital health applications in Germany -Perspectives and experiences of general practitioners with an affinity for their use</title>
		<author>
			<persName><forename type="first">J</forename><surname>Wangler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Jansky</surname></persName>
		</author>
		<idno type="DOI">10.1080/13814788.2023.2186396</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_wxs3nwQ">Eur. J. Gen. Pract</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page">2186396</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wangler, J. &amp; Jansky, M. Two years of approved digital health applications in Germany -Perspectives and experiences of general practitioners with an affinity for their use. Eur. J. Gen. Pract. 29, 2186396 (2023).</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main" xml:id="_rtYR5ns">Realworld usage of digital health applications (DiGA) in rheumatology: results from a German patient survey</title>
		<author>
			<persName><forename type="first">H</forename><surname>Labinsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Gupta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Raimondo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Schett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Knitza</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00296-022-05261-7</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_utkYrWN">Rheumatol. Int</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="713" to="719" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Labinsky, H., Gupta, L., Raimondo, M. G., Schett, G. &amp; Knitza, J. Real- world usage of digital health applications (DiGA) in rheumatology: results from a German patient survey. Rheumatol. Int. 43, 713-719 (2023).</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main" xml:id="_PzqFeEf">One year of digital health applications (DiGA) in Germany -Rheumatologists&apos; perspectives</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Richter</surname></persName>
		</author>
		<idno type="DOI">10.3389/fmed.2022.1000668</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_A74SG9Y">Front. Med</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">1000668</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Richter, J. G. et al. One year of digital health applications (DiGA) in Germany -Rheumatologists&apos; perspectives. Front. Med. 9, 1000668 (2022).</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main" xml:id="_mF2TjTy">Digitale Gesundheitsanwendungen (DiGA) im Spannungsfeld von Fortschritt und Kritik</title>
		<author>
			<persName><forename type="first">H</forename><surname>Schlieter</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00103-023-03804-2</idno>
		<ptr target="https://doi.org/10.1007/s00103-023-03804-2" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_bj6d779">Bundesgesundheitsblatt -Gesundheitsforschung -Gesundheitsschutz</title>
		<imprint>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Schlieter, H. et al. Digitale Gesundheitsanwendungen (DiGA) im Spannungsfeld von Fortschritt und Kritik. Bundesgesundheitsblatt - Gesundheitsforschung -Gesundheitsschutz (2023) https://doi.org/ 10.1007/s00103-023-03804-2.</note>
</biblStruct>

<biblStruct xml:id="b20">
	<monogr>
		<title level="m" type="main" xml:id="_K8q4RJm">Rahmenvereinbarung nach § 134 Abs</title>
		<author>
			<persName><surname>Gkv Spitzenverband</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2023">2023</date>
			<publisher>SGB V</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">GKV Spitzenverband. Rahmenvereinbarung nach § 134 Abs. 4 und 5 SGB V. (2023).</note>
</biblStruct>

<biblStruct xml:id="b21">
	<monogr>
		<author>
			<persName><surname>Gkv Spitzenverband</surname></persName>
		</author>
		<ptr target="https://www.gkv-spitzenverband.de/media/dokumente/krankenversicherung_1/telematik/digitales/2023_DiGA_Bericht_GKV-Spitzenverband.pdf" />
		<title level="m" xml:id="_uDEPHUD">Bericht des GKV-Spitzenverbandes über die Inanspruchnahme und Entwicklung der Versorgung mit Digitalen Gesundheitsanwendungen</title>
		<imprint>
			<date type="published" when="2023-01-10">2023. January 10, 2024</date>
		</imprint>
	</monogr>
	<note>DiGA-Bericht</note>
	<note type="raw_reference">GKV Spitzenverband. Bericht des GKV-Spitzenverbandes über die Inanspruchnahme und Entwicklung der Versorgung mit Digitalen Gesundheitsanwendungen (DiGA-Bericht) (2023). https://www.gkv- spitzenverband.de/media/dokumente/krankenversicherung_1/ telematik/digitales/2023_DiGA_Bericht_GKV-Spitzenverband.pdf (Accessed January 10, 2024).</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main" xml:id="_qQh2F3d">Digital therapeutics from bench to bedside</title>
		<author>
			<persName><forename type="first">C</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Shin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_pBwnxwG">Npj Digit. Med</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="1" to="10" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wang, C., Lee, C. &amp; Shin, H. Digital therapeutics from bench to bedside. Npj Digit. Med. 6, 1-10 (2023).</note>
</biblStruct>

<biblStruct xml:id="b23">
	<monogr>
		<title level="m" type="main" xml:id="_eDQfv3q">DiGA Guide</title>
		<ptr target="https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/3_Downloads/Gesetze_und_Verordnungen/GuV/D/DiGA-Leitfaden_2020.pdf" />
		<imprint>
			<date type="published" when="2024-01-16">January 16, 2024</date>
			<publisher>BfArM</publisher>
		</imprint>
	</monogr>
	<note>Initial 2020 Version</note>
	<note type="raw_reference">BfArM. DiGA Guide (Initial 2020 Version). https://www. bundesgesundheitsministerium.de/fileadmin/Dateien/3_Downloads/ Gesetze_und_Verordnungen/GuV/D/DiGA-Leitfaden_2020.pdf (Accessed January 16, 2024).</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main" xml:id="_XZNRBTd">Examining Diversity in Digital Therapeutics Clinical Trials: Descriptive Analysis</title>
		<author>
			<persName><forename type="first">J</forename><surname>Adu-Brimpong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Pugh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Darko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Shieh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_RbZjpny">J. Med. Internet Res</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page">37447</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Adu-Brimpong, J., Pugh, J., Darko, D. A. &amp; Shieh, L. Examining Diversity in Digital Therapeutics Clinical Trials: Descriptive Analysis. J. Med. Internet Res. 25, e37447 (2023).</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main" xml:id="_R2nkshn">Gender differences in the utilization of health care services</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">D</forename><surname>Bertakis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Azari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Helms</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Callahan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Robbins</surname></persName>
		</author>
		<idno type="DOI">10.1089/15246090152563579</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_n7TYAyj">J. Fam. Pract</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="147" to="152" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bertakis, K. D., Azari, R., Helms, L. J., Callahan, E. J. &amp; Robbins, J. A. Gender differences in the utilization of health care services. J. Fam. Pract. 49, 147-152 (2000).</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main" xml:id="_EhZFGKw">Assessment of ownership of smart devices and the acceptability of digital health data sharing</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M H</forename><surname>Shandhi</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41746-024-01030-x</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_TahPnHW">Npj Digit. Med</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="1" to="10" />
			<date type="published" when="2024">2024</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Shandhi, M. M. H. et al. Assessment of ownership of smart devices and the acceptability of digital health data sharing. Npj Digit. Med. 7, 1-10 (2024).</note>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main" xml:id="_qvdxAR4">Digital health applications and the fast-track pathway to public health coverage in Germany: challenges and opportunities based on first results</title>
		<author>
			<persName><forename type="first">H</forename><surname>Lantzsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Eckhardt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Campione</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Busse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Henschke</surname></persName>
		</author>
		<idno type="DOI">10.1186/s12913-022-08500-6</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_WZZJVTu">BMC Health Serv. Res</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page">1182</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lantzsch, H., Eckhardt, H., Campione, A., Busse, R. &amp; Henschke, C. Digital health applications and the fast-track pathway to public health coverage in Germany: challenges and opportunities based on first results. BMC Health Serv. Res. 22, 1182 (2022).</note>
</biblStruct>

<biblStruct xml:id="b28">
	<monogr>
		<idno type="DOI">10.1055/a-2369-5903</idno>
		<ptr target="https://digitalversorgt.de/wp-content/uploads/2024/01/DiGA-Report-2023.pdf" />
		<title level="m" xml:id="_FFEKHxJ">Marktentwicklung digitaler Gesundheitsanwendungen</title>
		<imprint>
			<publisher>Spitzenverband Digitale Gesundheitswirtschaft</publisher>
			<date type="published" when="2024-01-10">January 10, 2024</date>
		</imprint>
	</monogr>
	<note>DiGA-Report</note>
	<note type="raw_reference">Spitzenverband Digitale Gesundheitswirtschaft. Marktentwicklung digitaler Gesundheitsanwendungen (DiGA-Report). https://digitalv ersorgt.de/wp-content/uploads/2024/01/DiGA-Report-2023.pdf (Accessed January 10, 2024).</note>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main" xml:id="_MaCVQaJ">Rating analysis and BERTopic modeling of consumer versus regulated mHealth app reviews in Germany</title>
		<author>
			<persName><forename type="first">M</forename><surname>Uncovska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Freitag</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Meister</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Fehring</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41746-023-00862-3</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_pvVEHrt">Npj Digit. Med</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="1" to="15" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Uncovska, M., Freitag, B., Meister, S. &amp; Fehring, L. Rating analysis and BERTopic modeling of consumer versus regulated mHealth app reviews in Germany. Npj Digit. Med. 6, 1-15 (2023).</note>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main" xml:id="_W2N8nky">Gesetz Zur Beschleunigung Der Digitalisierung Des Gesundheitswesens (Digital-Gesetz -DigiG)</title>
		<author>
			<persName><forename type="first">Deutscher</forename><surname>Bundestag</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41746-024-01137-1</idno>
		<idno>Drucksache 20/9048</idno>
		<ptr target="https://doi.org/10.1038/s41746-024-01137-1" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_m4gKSP2">Digital Act</title>
		<imprint>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Deutscher Bundestag. Gesetz Zur Beschleunigung Der Digitalisierung Des Gesundheitswesens (Digital-Gesetz -DigiG) [Digital Act]. Drucksache 20/9048 (2023). https://doi.org/10.1038/s41746-024-01137-1</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main" xml:id="_Q5hq73f">Gesetz Zur Verbesserten Nutzung von Gesundheitsdaten [Health Data Use Act</title>
		<author>
			<persName><forename type="first">Deutscher</forename><surname>Bundestag</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_dnyp2jG">Drucksache</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page">9046</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Deutscher Bundestag. Gesetz Zur Verbesserten Nutzung von Gesundheitsdaten [Health Data Use Act]. Drucksache 20/9046 (2023).</note>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main" xml:id="_QBY74Hk">Initial Draft of: Gesetz Zur Beschleunigung Der Digitalisierung Des Gesundheitswesens (Digital-Gesetz -DigiG)</title>
		<author>
			<persName><forename type="first">Deutscher</forename><surname>Bundestag</surname></persName>
		</author>
		<idno type="DOI">10.1055/a-2162-9696</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_uATuTGn">Digital Act</title>
		<imprint>
			<biblScope unit="page" from="435" to="458" />
			<date type="published" when="2023">09. 2023. 2023</date>
		</imprint>
	</monogr>
	<note>Drucksache</note>
	<note type="raw_reference">Deutscher Bundestag. Initial Draft of: Gesetz Zur Beschleunigung Der Digitalisierung Des Gesundheitswesens (Digital-Gesetz -DigiG) [Digital Act] (09/2023). Drucksache 435/23 (2023).</note>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main" xml:id="_tzdVYSC">Understanding inherent influencing factors to digital health adoption in general practices through a mixed-methods analysis</title>
		<author>
			<persName><forename type="first">L</forename><surname>Weik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Fehring</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mortsiefer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Meister</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41746-024-01049-0</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_h2YeHty">Npj Digit. Med</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="1" to="16" />
			<date type="published" when="2024">2024</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Weik, L., Fehring, L., Mortsiefer, A. &amp; Meister, S. Understanding inherent influencing factors to digital health adoption in general practices through a mixed-methods analysis. Npj Digit. Med. 7, 1-16 (2024).</note>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main" xml:id="_KQbJhpu">Success Factors for Scaling Up the Adoption of Digital Therapeutics Towards the Realization of P5</title>
		<author>
			<persName><forename type="first">A</forename><surname>Prodan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_UpzcAwT">Med. Front. Med</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">854665</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Prodan, A. et al. Success Factors for Scaling Up the Adoption of Digital Therapeutics Towards the Realization of P5. Med. Front. Med. 9, 854665 (2022).</note>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main" xml:id="_ypPsdtU">Health app policy: international comparison of nine countries&apos; approaches</title>
		<author>
			<persName><forename type="first">A</forename><surname>Essén</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41746-022-00573-1</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Dt99tA3">Npj Digit. Med</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="1" to="10" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Essén, A. et al. Health app policy: international comparison of nine countries&apos; approaches. Npj Digit. Med. 5, 1-10 (2022).</note>
</biblStruct>

<biblStruct xml:id="b36">
	<monogr>
		<idno type="DOI">10.1038/s41746-025-01697-w</idno>
		<ptr target="https://eithealth.eu/european-taskforce-for-harmonised-evaluations-of-digital-medical-devices-dmds/" />
		<title level="m" xml:id="_FAHSfqM">European Taskforce for Harmonised Evaluations of Digital Medical Devices (DMDs)</title>
		<imprint>
			<date type="published" when="2024-03-02">March 2, 2024</date>
		</imprint>
	</monogr>
	<note>EIT Health</note>
	<note type="raw_reference">European Taskforce for Harmonised Evaluations of Digital Medical Devices (DMDs). EIT Health https://eithealth.eu/european-taskforce- for-harmonised-evaluations-of-digital-medical-devices-dmds/ (Accessed March 2, 2024).</note>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title/>
		<idno type="DOI">10.54941/ahfe1002093</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_FZnJs9W">Digital Medical Devices: Paths to European Harmonisation -Summary Report</title>
		<imprint/>
		<respStmt>
			<orgName>EIT Health</orgName>
		</respStmt>
	</monogr>
	<note type="raw_reference">EIT Health. Digital Medical Devices: Paths to European Harmonisation -Summary Report.</note>
</biblStruct>

<biblStruct xml:id="b38">
	<monogr>
		<ptr target="https://www.bertelsmann-stiftung.de/fileadmin/files/Projekte/Der_digitale_Patient/VV_SHS_Europe_eng.pdf" />
		<title level="m" xml:id="_2KxwWEa">Summary #SmartHealthSystems -Focus Europe</title>
		<imprint>
			<publisher>Bertelsmann Stiftung</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Bertelsmann Stiftung. Summary #SmartHealthSystems -Focus Europe. https://www.bertelsmann-stiftung.de/fileadmin/files/ Projekte/Der_digitale_Patient/VV_SHS_Europe_eng.pdf.</note>
</biblStruct>

<biblStruct xml:id="b39">
	<monogr>
		<author>
			<persName><surname>Gkv Spitzenverband</surname></persName>
		</author>
		<ptr target="https://www.gkv-spitzenverband.de/media/dokumente/krankenversicherung_1/telematik/digitales/2022_DiGA_Bericht_BMG.pdf" />
		<title level="m" xml:id="_sPFzefN">Bericht des GKV-Spitzenverbandes über die Inanspruchnahme und Entwicklung der Versorgung mit Digitalen Gesundheitsanwendungen</title>
		<imprint>
			<date type="published" when="2022-01-10">2022. January 10, 2024</date>
		</imprint>
	</monogr>
	<note>DiGA-Bericht</note>
	<note type="raw_reference">GKV Spitzenverband. Bericht des GKV-Spitzenverbandes über die Inanspruchnahme und Entwicklung der Versorgung mit Digitalen Gesundheitsanwendungen (DiGA-Bericht) (2022). https://www.gkv- spitzenverband.de/media/dokumente/krankenversicherung_1/ telematik/digitales/2022_DiGA_Bericht_BMG.pdf (Accessed January 10, 2024).</note>
</biblStruct>

<biblStruct xml:id="b40">
	<monogr>
		<author>
			<persName><surname>Gkv Spitzenverband</surname></persName>
		</author>
		<ptr target="https://www.gkv-spitzenverband.de/media/dokumente/krankenversicherung_1/telematik/digitales/2021_DiGA_Bericht_final_barrierefrei.pdf" />
		<title level="m" xml:id="_eKvb73B">Bericht des GKV-Spitzenverbandes über die Inanspruchnahme und Entwicklung der Versorgung mit Digitalen Gesundheitsanwendungen</title>
		<imprint>
			<date type="published" when="2021-01-12">2021. January 12, 2024</date>
		</imprint>
	</monogr>
	<note>DiGA-Bericht</note>
	<note type="raw_reference">GKV Spitzenverband. Bericht des GKV-Spitzenverbandes über die Inanspruchnahme und Entwicklung der Versorgung mit Digitalen Gesundheitsanwendungen (DiGA-Bericht) (2021). https://www.gkv- spitzenverband.de/media/dokumente/krankenversicherung_1/ telematik/digitales/2021_DiGA_Bericht_final_barrierefrei.pdf (Accessed January 12, 2024).</note>
</biblStruct>

<biblStruct xml:id="b41">
	<monogr>
		<idno type="DOI">10.1093/gmo/9781561592630.article.l2093722</idno>
		<ptr target="https://fbeta.de/diga-analyzer/" />
		<title level="m" xml:id="_hX2BX65">DiGA-Analyzer</title>
		<imprint>
			<publisher>_fbeta GmbH</publisher>
			<date type="published" when="2024-01-29">January 29, 2024</date>
		</imprint>
	</monogr>
	<note type="raw_reference">_fbeta GmbH. DiGA-Analyzer. https://fbeta.de/diga-analyzer/ (Accessed January 29, 2024).</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
